Evotec SE (EVO) analyst actions
Rating and price-target actions on EVO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the EVO overview →
1 measured EVO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation | Press release | -0.21% | +1.66% |
Keep exploring
More EVO: earnings → · SEC filings → · EVO overview →
Other Financial Services names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pimco Municipal Income Fund II Common Shares of Beneficial Interest (PML) | 112 | -0.06% | 36% |
| Eaton Vance New York Municipal Bond Fund Common Shares of Beneficial Interest, $.01 par value (ENX) | 110 | 0.00% | 50% |
| RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP) | 110 | 0.00% | 50% |
| Virginia National Bankshares Corporation (VABK) | 110 | +0.25% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.